Neoantigen quality predicts immunoediting in survivors of pancreatic cancer.

ABSTRACT: Cancer immunoediting¹ is a hallmark of cancer² that predicts that lymphocytes kill more immunogenic cancer cells to cause less immunogenic clones to dominate a population. Although proven in mice^1,3, whether immunoediting occurs naturally in human cancers remains unclear. Here, to address this, we investigate how 70 human pancreatic cancers evolved over 10 years. We find that, despite having more time to accumulate mutations, rare long-term survivors of pancreatic cancer who have stronger T cell activity in primary tumours develop genetically less heterogeneous recurrent tumours with fewer immunogenic mutations (neoantigens). To quantify whether immunoediting underlies these observations, we infer that a neoantigen is immunogenic (high-quality) by two featu

SUBMITTER: Luksza M 

PROVIDER: S-EPMC9177421 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature